Short- and Long-Term Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Patients with Rheumatoid Arthritis and an Inadequate Response to TNF Inhibitors: Analyses of Pooled Phase 2, Phase 3, and Long-Term Extension Studies.

被引：0
|
作者：
Burmester, G. [1 ]
Blanco, Ricardo [2 ]
Rubbert-Roth, Andrea [3 ]
Hendrikx, Thijs [4 ]
Kwok, Kenneth [5 ]
Bradley, John [6 ]
Zwillich, Samuel H. [6 ]
Benda, Birgitta [7 ]
Mebus, Charles A. [6 ]
机构：
[1] Charite, D-13353 Berlin, Germany
[2] Hosp Univ Marques De Valdecilla, Santander, Spain
[3] Univ Cologne, D-50931 Cologne, Germany
[4] Pfizer Bv, Capelle Aan Den Ijssel, Netherlands
[5] Pfizer Inc, New York, NY USA
[6] Pfizer Inc, Groton, CT 06340 USA
[7] Pfizer Inc, Collegeville, PA USA
来源：
ARTHRITIS AND RHEUMATISM | 2012年 / 64卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
L12
引用
收藏
页码：4172 / 4172
页数：1
相关论文
共 50 条
  • [21] Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study
    Papp, Kim A.
    Krueger, James G.
    Feldman, Steven R.
    Langley, Richard G.
    Thaci, Diamant
    Torii, Hideshi
    Tyring, Stephen
    Wolk, Robert
    Gardner, Annie
    Mebus, Charles
    Tan, Huaming
    Luo, Yingchun
    Gupta, Pankaj
    Mallbris, Lotus
    Tatulych, Svitlana
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : 841 - 850
  • [22] Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study
    Hisashi Yamanaka
    Yoshiya Tanaka
    Tsutomu Takeuchi
    Naonobu Sugiyama
    Hirotoshi Yuasa
    Shigeyuki Toyoizumi
    Yosuke Morishima
    Tomohiro Hirose
    Samuel Zwillich
    Arthritis Research & Therapy, 18
  • [23] Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study
    Yamanaka, Hisashi
    Tanaka, Yoshiya
    Takeuchi, Tsutomu
    Sugiyama, Naonobu
    Yuasa, Hirotoshi
    Toyoizumi, Shigeyuki
    Morishima, Yosuke
    Hirose, Tomohiro
    Zwillich, Samuel
    ARTHRITIS RESEARCH & THERAPY, 2016, 18
  • [24] Tofacitinib (CP-690,550), An Oral Janus Kinase Inhibitor: Analysis of Infections and All-Cause Mortality Across Phase 3 and Long-Term Extension Studies in Patients with Rheumatoid Arthritis.
    Cohen, S.
    Radominski, S. C.
    Asavatanabodee, P.
    Wood, S. P.
    Soma, K.
    Nduaka, C. I.
    Wang, L.
    Gruben, D.
    Valdez, H.
    Zwillich, S. H.
    Bradley, J.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S153 - S153
  • [25] Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies
    Schulze-Koops, Hendrik
    Strand, Vibeke
    Nduaka, Chudy
    DeMasi, Ryan
    Wallenstein, Gene
    Kwok, Kenneth
    Wang, Lisy
    RHEUMATOLOGY, 2017, 56 (01) : 46 - 57
  • [26] Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies
    Genovese, Mark C.
    Durez, Patrick
    Fleischmann, Roy
    Tanaka, Yoshiya
    Furst, Daniel
    Yamanaka, Hisashi
    Korneva, Elena
    Vasyutin, Igor
    Takeuchi, Tsutomu
    EUROPEAN JOURNAL OF RHEUMATOLOGY, 2021, 8 (03) : 120 - 129
  • [27] Tofacitinib in the treatment of Indian patients with rheumatoid arthritis: A post hoc analysis of efficacy and safety in Phase 3 and long-term extension studies over 7 years
    Chopra, Arvind
    Shobha, Vineeta
    Chandrashekara, Srikantiah
    Veeravalli, Sarath C. M.
    Sharma, Reena
    Rao, Uppuluri R.
    Pandya, Sapan
    Wagh, Shrikant
    Kadel, Jugal K.
    Thorat, Amit, V
    Adhav, Charles
    Estrella, Paul Santos
    Yu, Wei
    Kwok, Kenneth
    Wouters, Ann
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2020, 23 (07) : 882 - 897
  • [28] Long-term efficacy and safety of a repeat treatment course of rituximab in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors
    Keystone, E.
    Fleischmann, R.
    Emery, P.
    Chubick, A.
    Dougados, M.
    Baldassares, A. R.
    Bathon, J. M.
    Hessey, E.
    Totoritis, M.
    Cooper, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 323 - 324
  • [29] Long-term efficacy and safety of a repeat treatment course of rituximab in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors
    Keystone, E.
    Pope, J. E.
    Fleischmann, R.
    Emery, P.
    Chubick, A.
    Dougados, M.
    Baldassare, A. R.
    Bathon, J. M.
    Hessey, E.
    Totoritis, M.
    Cooper, S.
    JOURNAL OF RHEUMATOLOGY, 2007, 34 (07) : 1617 - 1618
  • [30] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: Open-Label, Long-term Extension Study
    Lichtenstein, Gary R.
    Loftus, Edward V., Jr.
    Bloom, Stuart
    Lawendy, Nervin
    Friedman, Gary S.
    Zhang, Haiying
    Wang, Wenjin
    Thorpe, Andrew J.
    Nduaka, Chudy I.
    Su, Chinyu
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S395 - S395
12345